{"filing":{"accession_number":"0001683168-26-004116","cik":"0001402328","ticker":"SBFMW","company_name":"Sunshine Biopharma Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"sunshine_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826004116/sunshine_8k.htm"},"events":[{"id":10246,"run_id":8986,"accession_number":"0001683168-26-004116","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Sunshine Biopharma entered into a placement agent agreement for a public offering of 11.16 million Common Units and 840,000 Pre-Funded Units, generating approximately $6 million in gross proceeds, with highly dilutive pre-funded warrants exercisable at $0.00001 and Series C warrants exercisable at $0.50.","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-05-19","form":"8-K","submitted_at":null,"items":[{"id":372,"accession_number":"0001683168-26-004116","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Sunshine Biopharma entered into a placement agent agreement for a public offering of 11.16 million Common Units and 840,000 Pre-Funded Units, generating approximately $6 million in gross proceeds. The offering includes pre-funded warrants exercisable at $0.00001 and Series C warrants exercisable at $0.50, both of which are highly dilutive instruments. This is a classic dilutive equity issuance disclosed under Item 1.01, material to investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:46:07.048424+00:00","company_name":"","ticker":null,"filing_date":""},{"id":373,"accession_number":"0001683168-26-004116","item_number":"8.01","item_title":"Other Information.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the pricing and closing of an offering involving pre-funded warrants and Series C warrants, as evidenced by the Placement Agent Agreement and warrant forms filed as exhibits. This represents a dilutive equity issuance that would materially affect existing shareholders' ownership percentages and is a significant capital-raising event for a small-cap biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:46:07.048424+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":372,"accession_number":"0001683168-26-004116","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Sunshine Biopharma entered into a placement agent agreement for a public offering of 11.16 million Common Units and 840,000 Pre-Funded Units, generating approximately $6 million in gross proceeds. The offering includes pre-funded warrants exercisable at $0.00001 and Series C warrants exercisable at $0.50, both of which are highly dilutive instruments. This is a classic dilutive equity issuance disclosed under Item 1.01, material to investors assessing ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:46:07.048424+00:00","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-05-19"},{"id":373,"accession_number":"0001683168-26-004116","item_number":"8.01","item_title":"Other Information.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses the pricing and closing of an offering involving pre-funded warrants and Series C warrants, as evidenced by the Placement Agent Agreement and warrant forms filed as exhibits. This represents a dilutive equity issuance that would materially affect existing shareholders' ownership percentages and is a significant capital-raising event for a small-cap biopharmaceutical company.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:46:07.048424+00:00","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-05-19"}]}